A meta-analysis of 38 studies found semaglutide significantly reduced heart failure hospitalizations (76%), cardiovascular death (17%), all-cause death (21%), heart attacks (24%), and stroke (35% in diabetic patients) in people with overweight or obesity.
76% reduction in HF hospitalizationSemaglutide dramatically reduced heart failure hospitalizations (RR 0.24) across pooled studies in overweight/obese patients, alongside 17% fewer cardiovascular deaths and 21% fewer deaths from any cause
What the researchers found
The meta-analysis found statistically significant reductions across multiple cardiovascular endpoints:
- Hospitalization for heart failure: RR 0.24 (95% CI 0.12–0.57), a 76% reduction
- Cardiovascular death: RR 0.83 (95% CI 0.71–0.98), a 17% reduction
- All-cause death: RR 0.79 (95% CI 0.70–0.89), a 21% reduction
- Non-fatal myocardial infarction: RR 0.76 (95% CI 0.66–0.88), a 24% reduction
- Coronary revascularization: RR 0.76 (95% CI 0.69–0.85), a 24% reduction
- Stroke in diabetic patients: RR 0.65 (95% CI 0.44–0.97), a 35% reduction
Subcutaneous administration showed stronger cardiovascular effects than oral semaglutide (subgroup difference p=0.05). Semaglutide was associated with a higher relative risk of most adverse effects evaluated, though treatment discontinuation rates were only significantly higher for oral semaglutide.
Why it matters
Cardiovascular disease is the leading cause of death among people with obesity, and finding drugs that reduce both weight and heart disease risk is a major clinical priority. This meta-analysis provides the most comprehensive evidence to date that semaglutide delivers meaningful cardiovascular protection — including a remarkable 76% reduction in heart failure hospitalizations. These findings support using semaglutide not just for weight management but as a cardiovascular protective therapy.
How the study worked
This was a systematic review and meta-analysis searching PubMed, LILACS, SciELO, Scopus, Web of Science, and the Cochrane Library. From 3,333 initial articles, 38 studies were included. Relative risk (RR) with 95% confidence intervals was calculated for cardiovascular outcomes and adverse effects. Heterogeneity was assessed using I² statistics. Subgroup analyses compared subcutaneous vs. oral administration routes and different oral doses.
What this study cannot tell us
The heart failure hospitalization finding, while dramatic (76% reduction), was based on only 2 studies with 1,045 participants total, limiting confidence. Some outcomes showed moderate heterogeneity (I² up to 0.66 for stroke). The meta-analysis included studies with different follow-up durations, semaglutide doses, and patient populations. The association with more adverse effects — particularly gastrointestinal — may affect real-world adherence. The analysis combined diabetes and non-diabetes populations for most outcomes.
How to read the evidence
This is a systematic review and meta-analysis — the highest level of evidence synthesis — incorporating 38 studies and up to 24,084 participants for key outcomes. Low heterogeneity for most endpoints strengthens the findings. However, some outcomes had limited study numbers, and adverse effect data indicate a significant tolerability trade-off.
When this study was published
Published in 2025, this meta-analysis captures the most recent clinical trial evidence for semaglutide, including data from the landmark SELECT and SUSTAIN trials.
The bigger picture
GLP-1 receptor agonists have emerged as potentially the most important new drug class in cardiovascular medicine since statins. This meta-analysis consolidates the evidence that semaglutide specifically offers broad cardiovascular protection in the overweight/obese population — spanning heart failure, coronary events, stroke, and mortality. The finding that subcutaneous administration may be more cardioprotective than oral has important implications for clinical prescribing decisions.
Questions still open
- Is the 76% reduction in heart failure hospitalization reproducible in larger, dedicated heart failure trials with semaglutide?
- Why does subcutaneous semaglutide appear more cardioprotective than oral — is it a pharmacokinetic or dose-related difference?
- Do the cardiovascular benefits of semaglutide persist long-term, or do they diminish if patients discontinue the drug?
Common questions
Does semaglutide protect the heart even in people without diabetes?
What are the downsides of semaglutide based on this analysis?
Read the original research
Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
International journal of obesity (2005), 49(1), 21-30
Citation
Cleto, André Saad; Schirlo, João Matheus; Beltrame, Mayara; Gomes, Victor Hugo Oliveira; Acras, Isabela Hellmann; Neiverth, Guinter Sponholz; Silva, Breno Bach; Juliatto, Beatriz Moreira Salles; Machozeki, Janete; Martins, Camila Marinelli. (2025). Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.. International journal of obesity (2005), 49(1), 21-30. https://doi.org/10.1038/s41366-024-01646-9